Therapeutic Delivery – Products

MaxCyte, Inc. has announced the signing of a strategic platform license with LG Chem Ltd.

In recent years, interest in lipid nanoparticle (LNP) research has increased due to promising opportunities for RNA-based therapy and gene-editing technology, and LNPs are showing promise as nucleic acid delivery vehicles in the pharmaceutical industry.

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS-CoV-2 vaccine for European clinical trials.

NovaXS Biotech Corp, developers of an in-home and needle-free drug delivery platform, for the first time unveiled its new prototype of its needle-free injection therapy smart medical device.

Blacktrace Holdings Ltd is excited to announce the launch of Particle Works, a spin out of Dolomite Microfluidics.

AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.

Lipid nanoparticles (LNP) play a key role in effectively protecting and transporting mRNA to target cells in mRNA-based vaccines and therapeutics. To ensure the quality and safety of LNP, lipid components and associated impurities/degradants need to be carefully characterized in raw materials and formulation.

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, offers effective performance on particle size reduction and cell disruption.

Beckman Coulter announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.

Grace will Exhibit at CPhI Worldwide 2021, Virtually and In-Person at Booth 11F26 at Fiero Milano, Milan, Italy.